Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Atomo Diagnostics Ltd. ( (AU:AT1) ) has issued an announcement.
Atomo Diagnostics has issued 5 million unquoted broker options, exercisable at $0.045 and expiring on 8 October 2028, as part of a previously announced transaction. The new options, which form a separate unquoted class not intended for ASX quotation, reflect the company’s continued use of incentive and financing structures to support its operations and market engagement.
The issuance underscores Atomo’s reliance on structured equity instruments to align broker interests with long-term company performance. While the options do not immediately affect quoted share capital, they represent potential future dilution and highlight the company’s ongoing capital management strategy in the competitive diagnostics market.
The most recent analyst rating on (AU:AT1) stock is a Hold with a A$0.03 price target. To see the full list of analyst forecasts on Atomo Diagnostics Ltd. stock, see the AU:AT1 Stock Forecast page.
More about Atomo Diagnostics Ltd.
Atomo Diagnostics Ltd. is an Australian-listed medical diagnostics company focused on developing and supplying rapid diagnostic test technologies. The company’s securities trade on the ASX under the code AT1, and it utilises various equity instruments to support its capital and financing activities within the healthcare sector.
Average Trading Volume: 2,045,256
Technical Sentiment Signal: Sell
Current Market Cap: A$25.93M
See more insights into AT1 stock on TipRanks’ Stock Analysis page.